Literature DB >> 22094004

Meningiomas in children and adolescents: a meta-analysis of individual patient data.

Rishi S Kotecha1, Elaine M Pascoe, Elisabeth J Rushing, Lucy B Rorke-Adams, Ted Zwerdling, Xing Gao, Xin Li, Stephanie Greene, Abbas Amirjamshidi, Seung-Ki Kim, Marco A Lima, Po-Cheng Hung, Fayçal Lakhdar, Nirav Mehta, Yuguang Liu, B Indira Devi, B Jayanand Sudhir, Morten Lund-Johansen, Flemming Gjerris, Catherine H Cole, Nicholas G Gottardo.   

Abstract

BACKGROUND: The epidemiological, prognostic, and therapeutic features of child and adolescent meningioma are poorly defined. Clinical knowledge has been drawn from small case series and extrapolation from adult studies. This study was done to pool and analyse the clinical evidence on child and adolescent meningioma.
METHODS: Searches of PubMed, Medline, and Embase identified 35 case series of child and adolescent meningioma completed over the past 21 years. Individual patient data were obtained from 30 studies via direct communication with investigators. Primary outcomes were relapse-free survival (RFS) and overall survival. Prognostic variables were extent of initial surgery, use of upfront radiotherapy, age, sex, presence of neurofibromatosis, tumour location, and tumour grade. RFS and overall survival were analysed using Kaplan-Meier survival curves and multivariable Cox regression models.
FINDINGS: From a total of 677 children and adolescents with meningioma, 518 were eligible for RFS analysis and 547 for overall survival analysis. Multivariable analysis showed that patients who underwent initial gross-total resection had better RFS (hazard ratio 0·16, 95% CI 0·10-0·25; p<0·0001) and overall survival (0·21, 0·11-0·39; p<0·0001) than those who had subtotal resection. No significant benefit was seen for upfront radiotherapy in terms of RFS (0·59, 0·30-1·16; p=0·128) or overall survival (1·10, 0·53-2·28; p=0·791). Patients with neurofibromatosis type 2 (NF2) had worse RFS than those without neurofibromatosis (2·36, 1·23-4·51; p=0·010). There was a significant change in overall survival with time between patients with NF2 compared with those without neurofibromatosis (1·45, 1·09-1·92; p=0·011); although overall survival was initially better for patients with NF2 than for those without neurofibromatosis, overall survival at 10 years was worse for patients with NF2. Patients with WHO grade III tumours had worse RFS than those with WHO grade I (3·90, 2·10-7·26; p<0·0001) and grade II tumours (2·49, 1·11-5·56; p=0·027).
INTERPRETATION: Extent of initial surgical resection is the strongest independent prognostic factor for child and adolescent meningioma. No benefit for upfront radiotherapy was noted. Hence, aggressive surgical management, to achieve gross-total resection, is the initial treatment of choice. In the event of a subtotal resection, repeat resection is recommended to achieve maximum extirpation. Close observation is warranted for patients who have a subtotal resection or who have WHO grade III tumours. Patients without neurofibromatosis should have a minimum 10-year follow-up, whereas patients with NF2 should be considered a special risk category, necessitating life-long follow-up. FUNDING: None.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22094004     DOI: 10.1016/S1470-2045(11)70275-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  52 in total

Review 1.  Pediatric meningiomas: a single-center experience with 15 consecutive cases and review of the literature.

Authors:  Marcelo Volpon Santos; Luciano Furlanetti; Elvis Terci Valera; Maria Sol Brassesco; Luiz Gonzaga Tone; Ricardo Santos de Oliveira
Journal:  Childs Nerv Syst       Date:  2012-06-06       Impact factor: 1.475

2.  Molecular typing of Meningiomas by Desorption Electrospray Ionization Mass Spectrometry Imaging for Surgical Decision-Making.

Authors:  David Calligaris; Daniel R Feldman; Isaiah Norton; Priscilla K Brastianos; Ian F Dunn; Sandro Santagata; Nathalie Y R Agar
Journal:  Int J Mass Spectrom       Date:  2015-02-01       Impact factor: 1.986

3.  Intracranial clear cell meningioma in two children with blood relations: two case reports and literature review.

Authors:  Zhiqi Li; Yi Zhang; Enming Wang; Zhiqiu Wang; Wengang Li; Shan Huang; Jun Li
Journal:  Childs Nerv Syst       Date:  2012-07-20       Impact factor: 1.475

Review 4.  The Role of Surgery in Meningiomas.

Authors:  Michele Bailo; Filippo Gagliardi; Nicola Boari; Antonella Castellano; Alfio Spina; Pietro Mortini
Journal:  Curr Treat Options Neurol       Date:  2019-09-27       Impact factor: 3.598

5.  Management of pediatric CNS meningiomas: CCHE-57357 experience in 39 cases.

Authors:  Mohamed A El Beltagy; Abd Elrahman Enayet; Mostafa M E Atteya; Mohamed Reda; Amal Refaat; Hala Taha; Soha Ahmed; Amal Abdelaziz
Journal:  Childs Nerv Syst       Date:  2019-05-24       Impact factor: 1.475

6.  Meningiomas of the pediatric skull base: a review.

Authors:  William C Gump
Journal:  J Neurol Surg B Skull Base       Date:  2014-09-21

7.  Clinical features and long-term outcomes of pediatric meningiomas.

Authors:  Jingdian Liu; Kai Zhao; Junwen Wang; Kai Shu
Journal:  Childs Nerv Syst       Date:  2021-07-22       Impact factor: 1.475

8.  Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961.

Authors:  Roger J Packer; Tianni Zhou; Emi Holmes; Gilbert Vezina; Amar Gajjar
Journal:  Neuro Oncol       Date:  2012-10-25       Impact factor: 12.300

Review 9.  Pediatric microcystic meningioma: a clinical, histological, and radiographic case-based review.

Authors:  Jotham Manwaring; Amir Ahmadian; Stacie Stapleton; Ignacio Gonzalez-Gomez; Luis Rodriguez; Carolyn Carey; Gerald F Tuite
Journal:  Childs Nerv Syst       Date:  2012-12-19       Impact factor: 1.475

Review 10.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.